Effects of Royal Jelly Supplementation in Chronic Kidney Disease
Recruiting · NCT06438445 · Interventional (participants receive a specific treatment) · Lead sponsor: Universidade Federal Fluminense
View the official record on ClinicalTrials.gov →Interventions studied
PlaceboReal Jelly
What this trial is about
The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- patients with CKD undergoing hemodialysis for more than 6 months
- patients with arteriovenous fistula (AVF) as vascular access.
Exclusion criteria
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
- patients with cancer, liver disease, and AIDS
Where it is running
1 location listed.
- Denise Mafra - Rio de Janeiro, Rio de Janeiro, Brazil